Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.37 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.31 |
| ▸ | F7 | P08709 | 5/20 | 0.31 |
| ▸ | F3 | P13726 | 5/20 | 0.31 |
| ▸ | PPARG | P37231 | 3/20 | 0.31 |
| ▸ | PPARD | Q03181 | 3/20 | 0.31 |
| ▸ | PPARA | Q07869 | 3/20 | 0.31 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29284354 | 1.00 | EP300 (0.37) | EP300KAT2BKAT5KAT8TSHR | |
| SCHEMBL22553079 | 1.00 | EP300 (0.37) | EP300KAT2BKAT5KAT8TSHR | |
| SCHEMBL19874772 | 1.00 | EP300 (0.37) | EP300KAT2BKAT5KAT8TSHR | |
| SCHEMBL25172428 | 1.00 | EP300 (0.37) | EP300KAT2BKAT5KAT8TSHR | |
| SCHEMBL21694513 | 1.00 | EP300 (0.37) | EP300KAT2BKAT5KAT8TSHR | |
| SCHEMBL25178871 | 1.00 | EP300 (0.37) | EP300KAT2BKAT5KAT8TSHR | |
| SCHEMBL19874771 | 1.00 | EP300 (0.37) | EP300KAT2BKAT5KAT8TSHR | |
| SCHEMBL25185580 | 1.00 | EP300 (0.37) | EP300KAT2BKAT5KAT8TSHR | |
| SCHEMBL21694515 | 1.00 | EP300 (0.37) | EP300KAT2BKAT5KAT8TSHR | |
| SCHEMBL6408228 | 0.98 | EP300 (0.40) | EP300KAT2BKAT5KAT8TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12031130-B2 | Composition for modifying target gene | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-09 | — | — | US | disclosed |
| US-11993570-B2 | Cationic lipids | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-28 | — | — | US | disclosed |
| EP-3733641-B1 | CATIONIC LIPIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-04-10 | — | — | EP | disclosed |
| US-20230257338-A1 | CATIONIC LIPIDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20210371854-A1 | COMPOSITION FOR MODIFYING TARGET GENE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-12-02 | — | — | US | disclosed |
| EP-3733641-A1 | CATIONIC LIPIDS | Takeda Pharmaceutical Company Limited (JP) | 2020-11-04 | — | — | EP | disclosed |
| EP-3733844-A1 | COMPOSITION FOR MODIFYING TARGET GENE | Kyoto University (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-20200331841-A1 | CATIONIC LIPIDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11993570-B2 | Cationic lipids | ELOVL5, LPCAT3, ELOVL3 | EP300 2836/4885KAT2B 1548/4885KAT5 402/4885 |
| US-20210371854-A1 | COMPOSITION FOR MODIFYING TARGET GENE | NSUN2, NSUN3, RNASE1 | EP300 2861/4885KAT2B 491/4885KAT5 280/4885 |
| US-12031130-B2 | Composition for modifying target gene | NSUN2, NSUN3, RNASE1 | EP300 2861/4885KAT2B 491/4885KAT5 280/4885 |
| US-20230257338-A1 | CATIONIC LIPIDS | ELOVL5, LPCAT3, ELOVL3 | EP300 2836/4885KAT2B 1548/4885KAT5 402/4885 |
| US-20200331841-A1 | CATIONIC LIPIDS | ELOVL5, LPCAT3, ELOVL3 | EP300 2836/4885KAT2B 1548/4885KAT5 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.